Skip to main navigation Skip to search Skip to main content

Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross-sectional multicenter study

  • Thomas Meyer
  • , Erma Salkic
  • , Torsten Grehl
  • , Ute Weyen
  • , Dagmar Kettemann
  • , Patrick Weydt
  • , René Günther
  • , Paul Lingor
  • , Jan Christoph Koch
  • , Susanne Petri
  • , Andreas Hermann
  • , Johannes Prudlo
  • , Julian Großkreutz
  • , Petra Baum
  • , Matthias Boentert
  • , Moritz Metelmann
  • , Jenny Norden
  • , Isabell Cordts
  • , Jochen H. Weishaupt
  • , Johannes Dorst
  • Albert Ludolph, Yasemin Koc, Bertram Walter, Christoph Münch, Susanne Spittel, Marie Dreger, André Maier, Péter Körtvélyessy
  • Free University of Berlin
  • APST Research GmbH
  • Alfried Krupp Krankenhaus
  • University of Bochum
  • University of Bonn
  • German Center for Neurodegenerative Diseases (DZNE)
  • Technische Universität Dresden
  • Technical University of Munich
  • University Medical Center
  • Hannover Medical School
  • Rostock University Medical Center
  • Universitätsmedizin Schleswig-Holstein
  • University Hospital Leipzig
  • Universitätsklinikum Münster
  • Heidelberg University
  • University Medical Center Ulm and Center of Excellence 'Metabolic Disorders'

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Background and purpose: The objective was to assess the performance of serum neurofilament light chain (sNfL) in amyotrophic lateral sclerosis (ALS) in a wide range of disease courses, in terms of progression, duration and tracheostomy invasive ventilation (TIV). Methods: A prospective cross-sectional study at 12 ALS centers in Germany was performed. sNfL concentrations were age adjusted using sNfL Z scores expressing the number of standard deviations from the mean of a control reference database and correlated to ALS duration and ALS progression rate (ALS-PR), defined by the decline of the ALS Functional Rating Scale. Results: In the total ALS cohort (n = 1378) the sNfL Z score was elevated (3.04; 2.46–3.43; 99.88th percentile). There was a strong correlation of sNfL Z score with ALS-PR (p < 0.001). In patients with long (5–10 years, n = 167) or very long ALS duration (>10 years, n = 94) the sNfL Z score was significantly lower compared to the typical ALS duration of <5 years (n = 1059) (p < 0.001). Furthermore, in patients with TIV, decreasing sNfL Z scores were found in correlation with TIV duration and ALS-PR (p = 0.002; p < 0.001). Conclusions: The finding of moderate sNfL elevation in patients with long ALS duration underlined the favorable prognosis of low sNfL. The strong correlation of sNfL Z score with ALS-PR strengthened its value as progression marker in clinical management and research. The lowering of sNfL in correlation with long TIV duration could reflect a reduction either in disease activity or in the neuroaxonal substrate of biomarker formation during the protracted course of ALS.

Original languageEnglish
Pages (from-to)1600-1610
Number of pages11
JournalEuropean Journal of Neurology
Volume30
Issue number6
DOIs
StatePublished - Jun 2023

Keywords

  • amyotrophic lateral sclerosis (ALS)
  • long disease duration
  • sNfL Z score
  • serum neurofilament light chain (sNfL)
  • tracheostomy invasive ventilation (TIV)

Fingerprint

Dive into the research topics of 'Performance of serum neurofilament light chain in a wide spectrum of clinical courses of amyotrophic lateral sclerosis—a cross-sectional multicenter study'. Together they form a unique fingerprint.

Cite this